Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer’s disease

References

• Gustavsson A, Norton N, Fast T, Froelich L, Georges J, Holzapfel D, Kirabali T, Krolak-Salmon P, Rossini PM, Ferretti MT, et al. Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzheimers Dement. 2022;19:658–670.
   PubMed Web of Science ®Google Scholar
• Nichols E, Szoeke CEI, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, Aichour MTE, Akinyemi RO, Alahdab F, Asgedom SW, et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(1):88–106.
   PubMed Web of Science ®Google Scholar
• Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, Abd-Allah F, Abdelalim A, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–1222.
   PubMed Web of Science ®Google Scholar
• Yang AC, Vest RT, Kern F, Lee DP, Agam M, Maat CA, Losada PM, Chen MB, Schaum N, Khoury N, et al. A human brain vascular atlas reveals diverse mediators of Alzheimer’s risk. Nature. 2022;603(7903):885–892.
   PubMed Web of Science ®Google Scholar
• Fang X, Zhang J, Roman RJ, Fan F. From 1901 to 2022, how far are we from truly understanding the pathogenesis of age-related dementia? Geroscience. 2022;44(3):1879–1883.
   PubMed Web of Science ®Google Scholar
• Zhang P, Xu S, Zhu Z, Xu J. Multi-target design strategies for the improved treatment of Alzheimer’s disease. Eur J Med Chem. 2019;176:228–247.
   PubMed Web of Science ®Google Scholar
• Sharma K. Cholinesterase inhibitors as Alzheimer’s therapeutics. Mol Med Rep. 2019;20(2):1479–1487.
   PubMed Web of Science ®Google Scholar
• Castro A, Martinez A. Targeting β-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr Pharm Des. 2006;12(33):4377–4387.
   PubMed Web of Science ®Google Scholar
• Tripathi AC, Upadhyay S, Paliwal S, Saraf SK. Privileged scaffolds as MAO inhibitors: retrospect and prospects. Eur J Med Chem. 2018;145:445–497.
   PubMed Web of Science ®Google Scholar
• Mpitimpiti AN, Petzer JP, Petzer A, Jordaan JHL, Lourens ACU. Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase. Mol Divers. 2019;23(4):897–913.
   PubMed Web of Science ®Google Scholar
• Santin Y, Resta J, Parini A, Mialet-Perez J. Monoamine oxidases in age-associated diseases: new perspectives for old enzymes. Ageing Res Rev. 2021;66:101256.
   PubMed Web of Science ®Google Scholar
• Ramsay RR. Molecular aspects of monoamine oxidase B. Prog Neuropsychopharmacol Biol Psychiatry. 2016;69:81–89.
   PubMed Web of Science ®Google Scholar
• Inaba-Hasegawa K, Akao Y, Maruyama W, Naoi M. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells. J Neural Transm. 2013;120(3):435–444.
   PubMed Web of Science ®Google Scholar
• Finberg JPM. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther. 2014;143(2):133–152.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Ahmad R, Khare SK. Alzheimer’s disease and its treatment by different approaches: a review. Eur J Med Chem. 2021;216:113320.
   PubMed Web of Science ®Google Scholar
• Knez D, Sova M, Kosak U, Gobec S. Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer’s disease. Future Med Chem. 2017;9(8):811–832.
   PubMed Web of Science ®Google Scholar
• Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem. 2008;51(3):347–372.
   PubMed Web of Science ®Google Scholar
• Benek O, Korabecny J, Soukup O. A perspective on multi-target drugs for Alzheimer’s disease. Trends Pharmacol Sci. 2020;41(7):434–445.
   PubMed Web of Science ®Google Scholar
• Mesiti F, Chavarria D, Gaspar A, Alcaro S, Borges F. The chemistry toolbox of multitarget-directed ligands for Alzheimer’s disease. Eur J Med Chem. 2019;181:111572.
   PubMed Web of Science ®Google Scholar
• Nozal V, García-Rubia A, Cuevas EP, Pérez C, Tosat-Bitrián C, Bartolomé F, Carro E, Ramírez D, Palomo V, Martínez A. From kinase inhibitors to multitarget ligands as powerful drug leads for Alzheimer’s disease using protein-templated synthesis. Angew Chem Int Ed Engl. 2021;60(35):19344–19354.
   PubMed Web of Science ®Google Scholar
• Savelieff MG, Nam G, Kang J, Lee HJ, Lee M, Lim MH. Development of multifunctional molecules as potential therapeutic candidates for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis in the last decade. Chem Rev. 2019;119(2):1221–1322.
   PubMed Web of Science ®Google Scholar
• Tumiatti V, Minarini A, Bolognesi ML, Milelli A, Rosini M, Melchiorre C. Tacrine derivatives and Alzheimer’s disease. Curr Med Chem. 2010;17(17):1825–1838.
   PubMed Web of Science ®Google Scholar
• Li SY, Jiang N, Xie SS, Wang KDG, Wang XB, Kong LY. Design, synthesis and evaluation of novel tacrine-rhein hybrids as multifunctional agents for the treatment of Alzheimer’s disease. Org Biomol Chem. 2014;12(5):801–814.
   PubMed Web of Science ®Google Scholar
• Faller P. Copper and zinc binding to amyloid-β: coordination, dynamics, aggregation, reactivity and metal-ion transfer. Chembiochem. 2009;10(18):2837–2845.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen LY, Yin WX, Yin J, Zhang SB, Liu CL. The chelation targeting metal-Aβ40 aggregates may lead to formation of Aβ40 oligomers. Dalton Trans. 2011;40(18):4830–4833.
   PubMed Web of Science ®Google Scholar
• Bolognin S, Drago D, Messori L, Zatta P. Chelation therapy for neurodegenerative diseases. Med Res Rev. 2009;29(4):547–570.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Rodríguez C, Sánchez de Groot N, Rimola A, Alvarez-Larena A, Lloveras V, Vidal-Gancedo J, Ventura S, Vendrell J, Sodupe M, González-Duarte P. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer’s disease. J Am Chem Soc. 2009;131(4):1436–1451.
   PubMed Web of Science ®Google Scholar
• Takao K, Kubota Y, Kamauchi H, Sugita Y. Synthesis and biological evaluation of pyrano [4,3-b][1] benzopyranone derivatives as monoamine oxidase and cholinesterase inhibitors. Bioorg Chem. 2019;83:432–437.
   PubMed Web of Science ®Google Scholar
• Seenuvasan M, Vinodhini G, Malar CG, Balaji N, Kumar KS. Magnetic nanoparticles: a versatile carrier for enzymes in bio-processing sectors. IET Nanobiotechnol. 2018;12(5):535–548.
   PubMed Web of Science ®Google Scholar
• Zhang F, Li SH, Liu C, Fang K, Jiang YM, Zhang JY, Lan J, Zhu L, Pang HQ, Wang G. Rapid screening for acetylcholinesterase inhibitors in Selaginella doederleinii hieron by using functionalized magnetic Fe3O4 nanoparticles. Talanta. 2022;243:123284.
   PubMed Web of Science ®Google Scholar
• Li CH, Wang WF, Stanislas N, Yang JL. Facile preparation of fluorescent water-soluble non-conjugated polymer dots and fabricating an acetylcholinesterase biosensor. RSC Adv. 2022;12(13):7911–7921.
   PubMed Web of Science ®Google Scholar
• Liao CZ, Sitzmann M, Pugliese A, Nicklaus MC. Software and resources for computational medicinal chemistry. Future Med Chem. 2011;3(8):1057–1085.
   PubMed Web of Science ®Google Scholar
• Zhou P, Hua F. Exploration of acetylcholinesterase inhibitors from flavonoids and flavonoid glycosides. Neurochem J. 2020;14(3):251–256.
   Google Scholar
• Gidaro MC, Astorino C, Petzer A, Carradori S, Alcaro F, Costa G, Artese A, Rafele G, Russo FM, Petzer JP, et al. Kaempferol as selective human MAO-A inhibitor: analytical detection in calabrian red wines, biological and molecular modeling studies. J Agric Food Chem. 2016;64(6):1394–1400.
   PubMed Web of Science ®Google Scholar
• Gogineni V, Nael MA, Chaurasiya ND, Elokely KM, McCurdy CR, Rimoldi JM, Cutler SJ, Tekwani BL, Leon F. Computationally assisted lead optimization of novel potent and selective MAO-B inhibitors. Biomedicines. 2021;9(10):1304.
   PubMed Web of Science ®Google Scholar
• Wang D, Chen NH, Taranto AG, Jin YT, Wen CC, Kong DX. Accelerating the identification of subtype selective inhibitors via three-dimensional biologically relevant spectrum (BRS-3D): The monoamine oxidase subtypes as a case study. Bioorg Chem. 2021;106:104503.
   PubMed Web of Science ®Google Scholar
• Kessel D. Photodynamic therapy: a brief history. J Clin Med. 2019;8(10):1581.
   PubMed Web of Science ®Google Scholar
• Paolino M, Rullo M, Maramai S, de Candia M, Pisani L, Catto M, Mugnaini C, Brizzi A, Cappelli A, Olivucci M, et al. Design, synthesis and biological evaluation of light-driven on-off multitarget AChE and MAO-B inhibitors. RSC Med Chem. 2022;13(7):873–883.
   PubMedGoogle Scholar
• Farina R, Pisani L, Catto M, Nicolotti O, Gadaleta D, Denora N, Soto-Otero R, Mendez-Alvarez E, Passos CS, Muncipinto G, et al. Structure-based design and optimization of multitarget-directed 2H-chromen-2-one derivatives as potent inhibitors of monoamine oxidase B and cholinesterases. J Med Chem. 2015;58(14):5561–5578.
   PubMed Web of Science ®Google Scholar
• Greenblatt HM, Dvir H, Silman I, Sussman JL. Acetylcholinesterase – a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer’s disease. J Mol Neurosci. 2003;20(3):369–383.
   PubMed Web of Science ®Google Scholar
• Agatonovic-Kustrin S, Kettle C, Morton DW. A molecular approach in drug development for Alzheimer’s disease. Biomed Pharmacother. 2018;106:553–565.
   PubMed Web of Science ®Google Scholar
• Milczek EM, Binda C, Rovida S, Mattevi A, Edmondson DE. The ‘gating’ residues ile199 and tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition. Febs J. 2011;278(24):4860–4869.
   PubMed Web of Science ®Google Scholar
• Hubalek F, Binda C, Li M, Herzig Y, Sterling J, Youdim MBH, Mattevi A, Edmondson DE. Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. J Med Chem. 2004;47(7):1760–1766.
   PubMed Web of Science ®Google Scholar
• Zhang C, Lv Y, Bai R, Xie Y. Structural exploration of multifunctional monoamine oxidase B inhibitors as potential drug candidates against Alzheimer’s disease. Bioorg Chem. 2021;114:105070.
   PubMed Web of Science ®Google Scholar
• De Colibus L, Li M, Binda C, Lustig A, Edmondson DE, Mattevi A. Three-dimensional structure of human monoamine oxidase A (MAO-A): relation to the structures of rat MAO-A and human MAO-B. Proc Natl Acad Sci U S A. 2005;102(36):12684–12689.
   PubMed Web of Science ®Google Scholar
• Li M, Binda C, Mattevi A, Edmondson DE. Functional role of the “aromatic cage” in human monoamine oxidase B: structures and catalytic properties of tyr435 mutant proteins. Biochemistry. 2006;45(15):4775–4784.
   PubMed Web of Science ®Google Scholar
• Więckowska A, Szałaj N, Góral I, Bucki A, Latacz G, Kiec-Kononowicz K, Bautista-Aguilera ÒM, Romero A, Ramos E, Egea J, et al. In vitro and in silico ADME-Tox profiling and safety significance of multifunctional monoamine oxidase inhibitors targeting neurodegenerative diseases. ACS Chem Neurosci. 2020;11(22):3793–3801.
   PubMed Web of Science ®Google Scholar
• del Pino J, Marco-Contelles J, Lopez-Munoz F, Romero A, Ramos E. Neuroinflammation signaling modulated by ASS234, a multitarget small molecule for Alzheimer’s disease therapy. ACS Chem Neurosci. 2018;9(12):2880–2885.
   PubMed Web of Science ®Google Scholar
• Marco-Contelles J, Unzeta M, Bolea I, Esteban G, Ramsay RR, Romero A, Martínez-Murillo R, Carreiras MC, Ismaili L. ASS234, as a new multi-target directed propargylamine for Alzheimer’s disease therapy. Front Neurosci. 2016;10:294.
   PubMed Web of Science ®Google Scholar
• Youdim MBH. Site-activated multi target iron chelators with acetylcholinesterase (AChE) and monoamine oxidase (MAO) inhibitory activities for Alzheimer’s disease therapy. J Neural Transm. 2022;129(5-6):715–721.
   PubMed Web of Science ®Google Scholar
• Weinstock M, Kirschbaum-Slager N, Lazarovici P, Bejar C, Youdim MBH, Shoham S. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann N Y Acad Sci. 2001;939:148–161.
   PubMed Web of Science ®Google Scholar
• Weinstock M, Gorodetsky E, Wang RH, Gross A, Weinreb O, Youdim MBH. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits. Neuropharmacology. 2002;43(6):999–1005.
   PubMed Web of Science ®Google Scholar
• Xu Y-X, Wang H, Li X-K, Dong S-N, Liu W-W, Gong Q, Wang T-D-Y, Tang Y, Zhu J, Li J, et al. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer’s disease. Eur J Med Chem. 2018;143:33–47.
   PubMed Web of Science ®Google Scholar
• Zhuang C, Zhang W, Sheng C, Zhang W, Xing C, Miao Z. Chalcone: A privileged structure in medicinal chemistry. Chem Rev. 2017;117(12):7762–7810.
   PubMed Web of Science ®Google Scholar
• Zhou B, Xing C. Diverse molecular targets for chalcones with varied bioactivities. Med Chem. 2015;5(8):388–404.
   PubMedGoogle Scholar
• Oh JM, Kang M-G, Hong A, Park J-E, Kim SH, Lee JP, Baek SC, Park D, Nam S-J, Cho M-L, et al. Potent and selective inhibition of human monoamine oxidase-B by 4-dimethylaminochalcone and selected chalcone derivatives. Int J Biol Macromol. 2019;137:426–432.
   PubMed Web of Science ®Google Scholar
• Lakshminarayanan B, Baek SC, Lee JP, Kannappan N, Mangiatordi GF, Nicolotti O, Subburaju T, Kim H, Mathew B. Ethoxylated head of chalcones as a new class of multi-targeted MAO inhibitors. Chemistryselect. 2019;4(21):6614–6619.
   Web of Science ®Google Scholar
• Sasidharan R, Eom BH, Heo JH, Park JE, Abdelgawad MA, Musa A, Gambacorta N, Nicolotti O, Manju SL, Mathew B, et al. Morpholine-based chalcones as dual-acting monoamine oxidase-B and acetylcholinesterase inhibitors: synthesis and biochemical investigations. J Enzyme Inhib Med Chem. 2021;36(1):188–197.
   PubMed Web of Science ®Google Scholar
• Mathew B, Oh JM, Baty RS, Batiha GE-S, Parambi DGT, Gambacorta N, Nicolotti O, Kim H. Piperazine-substituted chalcones: a new class of MAO-B, AChE, and BACE-1 inhibitors for the treatment of neurological disorders. Environ Sci Pollut Res Int. 2021;28(29):38855–38866.
   PubMed Web of Science ®Google Scholar
• Yamali C, Engin FS, Bilginer S, Tugrak M, Ozmen Ozgun D, Ozli G, Levent S, Saglik BN, Ozkay Y, Gul HI. Phenothiazine-based chalcones as potential dual-target inhibitors toward cholinesterases (AChE, BuChE) and monoamine oxidases (MAO-A, MAO-B). J Heterocycl Chem. 2021;58(1):161–171.
   Web of Science ®Google Scholar
• Jeong GS, Kaipakasseri S, Lee SR, Marraiki N, Batiha GE-S, Dev S, Palakkathondi A, Kavully FS, Gambacorta N, Nicolotti O, et al. Selected 1,3-benzodioxine-containing chalcones as multipotent oxidase and acetylcholinesterase inhibitors. ChemMedChem. 2020;15(23):2257–2263.
   PubMed Web of Science ®Google Scholar
• Sang Z, Song Q, Cao Z, Deng Y, Zhang L. Design, synthesis, and evaluation of chalcone-vitamin E-donepezil hybrids as multi-target-directed ligands for the treatment of Alzheimer’s disease. J Enzyme Inhib Med Chem. 2022;37(1):69–85.
   PubMedGoogle Scholar
• Sang Z, Song Q, Cao Z, Deng Y, Tan Z, Zhang L. Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer’s disease. Eur J Med Chem. 2021;216:113310.
   PubMed Web of Science ®Google Scholar
• Bai P, Wang K, Zhang P, Shi J, Cheng X, Zhang Q, Zheng C, Cheng Y, Yang J, Lu X, et al. Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer’s disease. Eur J Med Chem. 2019;183:111737.
   PubMed Web of Science ®Google Scholar
• Sang Z, Wang K, Shi J, Liu W, Tan Z. Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer’s disease. Eur J Med Chem. 2019;178:726–739.
   PubMed Web of Science ®Google Scholar
• Park DH, Venkatesan J, Kim SK, Ramkumar V, Parthiban P. Antioxidant properties of Mannich bases. Bioorg Med Chem Lett. 2012;22(20):6362–6367.
   PubMed Web of Science ®Google Scholar
• Roman G. Mannich bases in medicinal chemistry and drug design. Eur J Med Chem. 2015;89:743–816.
   PubMed Web of Science ®Google Scholar
• Buyukkidan N, Ozer S. Synthesis and characterization of Ni(ii) and Cu(ii) complexes derived from novel phenolic Mannich bases. Turk J Chem. 2013;37(1):101–110.
   Web of Science ®Google Scholar
• Bui TH, Le TT, Vu TT, Hoang XT, Luu VC, Vu DH, Tran KV. Design, synthesis and in vitro cytotoxic activity evaluation of new Mannich bases. B Korean Chem Soc. 2012;33(5):1586–1592.
   Web of Science ®Google Scholar
• Tian C, Qiang X, Song Q, Cao Z, Ye C, He Y, Deng Y, Zhang L. Flurbiprofen-chalcone hybrid Mannich base derivatives as balanced multifunctional agents against Alzheimer’s disease: Design, synthesis and biological evaluation. Bioorg Chem. 2020;94:103477.
   PubMed Web of Science ®Google Scholar
• Zhang X, Song Q, Cao Z, Li Y, Tian C, Yang Z, Zhang H, Deng Y. Design, synthesis and evaluation of chalcone Mannich base derivatives as multifunctional agents for the potential treatment of Alzheimer’s disease. Bioorg Chem. 2019;87:395–408.
   PubMed Web of Science ®Google Scholar
• Oh JM, Rangarajan TM, Chaudhary R, Singh RP, Singh M, Singh RP, Tondo AR, Gambacorta N, Nicolotti O, Mathew B, et al. Novel class of chalcone oxime ethers as potent monoamine oxidase-B and acetylcholinesterase inhibitors. Molecules. 2020;25(10):2356.
   PubMed Web of Science ®Google Scholar
• Oh JM, Rangarajan TM, Chaudhary R, Gambacorta N, Nicolotti O, Kumar S, Mathew B, Kim H. Aldoxime- and hydroxy-functionalized chalcones as highly potent and selective monoamine oxidase-B inhibitors. J Mol Struct. 2022;1250:131817.
   Web of Science ®Google Scholar
• Kumar B, Dwivedi AR, Sarkar B, Gupta SK, Krishnamurthy S, Mantha AK, Parkash J, Kumar V. 4,6-diphenylpyrimidine derivatives as dual inhibitors of monoamine oxidase and acetylcholinesterase for the treatment of Alzheimer’s disease. ACS Chem Neurosci. 2019;10(1):252–265.
   PubMed Web of Science ®Google Scholar
• Kumar B, Kumar V, Prashar V, Saini S, Dwivedi AR, Bajaj B, Mehta D, Parkash J, Kumar V. Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase. Eur J Med Chem. 2019;177:221–234.
   PubMed Web of Science ®Google Scholar
• Kurt BZ, Gazioglu I, Sonmez F, Kucukislamoglu M. Synthesis, antioxidant and anticholinesterase activities of novel coumarylthiazole derivatives. Bioorg Chem. 2015;59:80–90.
   PubMed Web of Science ®Google Scholar
• Xia-Hou ZR, Feng XF, Mei YF, Zhang YY, Yang T, Pan J, Yang JH, Wang YS. 5-Demethoxy-10'-ethoxyexotimarin F, a new coumarin with MAO-B inhibitory potential from Murraya exotica L. Molecules. 2022;27(15):4950.
   PubMed Web of Science ®Google Scholar
• Maliyakkal N, Ahmad I, Kumar S, Sudevan ST, Beeran AA, Patel H, Kim H, Mathew B. A structural approach to investigate halogen substituted MAO-B inhibitors using QSAR modeling, molecular dynamics, and conceptual DFT analysis. J Saudi Chem Soc. 2023;27(4):101675.
   Web of Science ®Google Scholar
• Joubert J, Foka GB, Repsold BP, Oliver DW, Kapp E, Malan SF. Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer’s disease. Eur J Med Chem. 2017;125:853–864.
   PubMed Web of Science ®Google Scholar
• Bester E, Petzer A, Petzer JP. Coumarin derivatives as inhibitors of D-amino acid oxidase and monoamine oxidase. Bioorg Chem. 2022;123:105791.
   PubMed Web of Science ®Google Scholar
• Lan JS, Ding Y, Liu Y, Kang P, Hou JW, Zhang XY, Xie SS, Zhang T. Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer’s disease. Eur J Med Chem. 2017;139:48–59.
   PubMed Web of Science ®Google Scholar
• Fonseca A, Matos MJ, Reis J, Duarte Y, Gutierrez M, Santana L, Uriarte E, Borges F. Exploring coumarin potentialities: development of new enzymatic inhibitors based on the 6-methyl-3-carboxamidocoumarin scaffold. RSC Adv. 2016;6(55):49764–49768.
   Web of Science ®Google Scholar
• Vina D, Matos MJ, Yanez M, Santana L, Uriarte E. 3-substituted coumarins as dual inhibitors of AChE and MAO for the treatment of Alzheimer’s disease. Medchemcomm. 2012;3(2):213–218.
   Web of Science ®Google Scholar
• Zhang Q, Hao C, Miao Y, Yun Y, Sun X, Pan Y, Sun J, Wang X. Design and synthesis of benzyl aminocoumarin and its anti-Alzheimer’s activity. New J Chem. 2021;45(37):17287–17300.
   Web of Science ®Google Scholar
• Rehuman NA, Oh JM, Nath LR, Khames A, Abdelgawad MA, Gambacorta N, Nicolotti O, Jat RK, Kim H, Mathew B. Halogenated coumarin-chalcones as multifunctional monoamine oxidase-B and butyrylcholinesterase inhibitors. Acs Omega. 2021;6(42):28182–28193.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Enriquez F, Vina D, Uriarte E, Laguna R, Matos MJ. 7-amidocoumarins as multitarget agents against neurodegenerative diseases: substitution pattern modulation. Chemmedchem. 2021;16(1):179–186.
   PubMed Web of Science ®Google Scholar
• Rullo M, Cipolloni M, Catto M, Colliva C, Miniero DV, Latronico T, de Candia M, Benicchi T, Linusson A, Giacche N, et al. Probing fluorinated motifs onto dual AChE-MAO B inhibitors: rational design, synthesis, biological evaluation, and early-ADME studies. J Med Chem. 2022;65(5):3962–3977.
   PubMed Web of Science ®Google Scholar
• He Q, Liu J, Lan JS, Ding J, Sun Y, Fang Y, Jiang N, Yang Z, Sun L, Jin Y, et al. Coumarin-dithiocarbamate hybrids as novel multitarget AChE and MAO-B inhibitors against Alzheimer’s disease: design, synthesis and biological evaluation. Bioorg Chem. 2018;81:512–528.
   PubMed Web of Science ®Google Scholar
• Pisani L, Iacobazzi RM, Catto M, Rullo M, Farina R, Denora N, Cellamare S, Altomare CD. Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors. Eur J Med Chem. 2019;161:292–309.
   PubMed Web of Science ®Google Scholar
• Carradori S, Silvestri R. New frontiers in selective human MAO-B inhibitors. J Med Chem. 2015;58(17):6717–6732.
   PubMed Web of Science ®Google Scholar
• Gaspar A, Reis J, Fonseca A, Milhazes N, Vina D, Uriarte E, Borges F. Chromone 3-phenylcarboxamides as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2011;21(2):707–709.
   PubMed Web of Science ®Google Scholar
• Gaspar A, Silva T, Yanez M, Vina D, Orallo F, Ortuso F, Uriarte E, Alcaro S, Borges F. Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors. J Med Chem. 2011;54(14):5165–5173.
   PubMed Web of Science ®Google Scholar
• Reis J, Cagide F, Estrada Valencia M, Teixeira J, Bagetta D, Perez C, Uriarte E, Oliveira PJ, Ortuso F, Alcaro S, et al. Multi-target-directed ligands for Alzheimer’s disease: discovery of chromone-based monoamine oxidase/cholinesterase inhibitors. Eur J Med Chem. 2018;158:781–800.
   PubMed Web of Science ®Google Scholar
• Wang XB, Yin FC, Huang M, Jiang N, Lan JS, Kong LY. Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer’s disease. RSC Med Chem. 2020;11(2):225–233.
   PubMedGoogle Scholar
• Estrada-Valencia M, Herrera-Arozamena C, Perez C, Vina D, Morales-Garcia JA, Perez-Castillo A, Ramos E, Romero A, Laurini E, Pricl S, et al. New flavonoid – N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer ' s disease endowed with neurogenic properties. J Enzyme Inhib Med Chem. 2019;34(1):712–727.
   PubMed Web of Science ®Google Scholar
• Łażewska D, Bajda M, Kaleta M, Zaręba P, Doroz-Płonka A, Siwek A, Alachkar A, Mogilski S, Saad A, Kuder K, et al. Rational design of new multitarget histamine H-3 receptor ligands as potential candidates for treatment of Alzheimer’s disease. Eur J Med Chem. 2020;207:112743.
   PubMed Web of Science ®Google Scholar
• Campora M, Canale C, Gatta E, Tasso B, Laurini E, Relini A, Pricl S, Catto M, Tonelli M. Multitarget biological profiling of new naphthoquinone and anthraquinone-based derivatives for the treatment of Alzheimer’s disease. ACS Chem Neurosci. 2021;12(3):447–461.
   PubMed Web of Science ®Google Scholar
• Onoda M, Fujita K. Iridium-catalyzed C-alkylation of methyl group on N-heteroaromatic compounds using alcohols. Org Lett. 2020;22(18):7295–7299.
   PubMed Web of Science ®Google Scholar
• Xu R, Xiao G, Li Y, Liu H, Song Q, Zhang X, Yang Z, Zheng Y, Tan Z, Deng Y. Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer’s disease. Bioorg Med Chem. 2018;26(8):1885–1895.
   PubMed Web of Science ®Google Scholar
• Liu Z, Shi Y, Zhang X, Yu G, Li J, Cong S, Deng Y. Discovery of novel 3-butyl-6-benzyloxyphthalide Mannich base derivatives as multifunctional agents against Alzheimer’s disease. Bioorg Med Chem. 2022;58:116660.
   PubMed Web of Science ®Google Scholar
• Nadeem MS, Khan JA, Kazmi I, Rashid U. Design, synthesis, and bioevaluation of indole core containing 2-arylidine derivatives of thiazolopyrimidine as multitarget inhibitors of cholinesterases and monoamine oxidase A/B for the treatment of Alzheimer disease. Acs Omega. 2022;7(11):9369–9379.
   PubMed Web of Science ®Google Scholar
• Denya I, Malan SF, Enogieru AB, Omoruyi SI, Ekpo OE, Kapp E, Zindo FT, Joubert J. Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer’s disease. Medchemcomm. 2018;9(2):357–370.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhang J, Wang H, Mao F, Bao K, Liu W, Zhu J, Li X, Zhang H, Li J. Rational design of novel selective dual-target inhibitors of acetylcholinesterase and monoamine oxidase B as potential anti-Alzheimer’s disease agents. ACS Chem Neurosci. 2019;10(1):482–496.
   PubMed Web of Science ®Google Scholar
• Osmaniye D, Evren AE, Saglik BN, Levent S, Ozkay Y, Kaplancikli ZA. Design, synthesis, biological activity, molecular docking, and molecular dynamics of novel benzimidazole derivatives as potential AChE/MAO-B dual inhibitors. Arch Pharm. 2022;355(3):e210045.
   Web of Science ®Google Scholar
• Tzvetkov NT, Stammler HG, Georgieva MG, Russo D, Faraone I, Balacheva AA, Hristova S, Atanasov AG, Milella L, Antonov L, et al. Carboxamides vs. Methanimines: crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors. Eur J Med Chem. 2019;179:404–422.
   PubMed Web of Science ®Google Scholar
• Karaca Ş, Osmaniye D, Sağlık BN, Levent S, Ilgın S, Özkay Y, Karaburun AÇ, Kaplancıklı ZA, Gundogdu-Karaburun N. Synthesis of novel benzothiazole derivatives and investigation of their enzyme inhibitory effects against Alzheimer’s disease. RSC Adv. 2022;12(36):23626–23636.
   PubMed Web of Science ®Google Scholar
• Chimenti F, Bolasco A, Secci D, Chimenti P, Granese A, Carradori S, Yanez M, Orallo F, Ortuso F, Alcaro S. Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors. Bioorg Med Chem. 2010;18(15):5715–5723.
   PubMed Web of Science ®Google Scholar
• Turan-Zitouni G, Hussein W, Sağlık BN, Tabbi A, Korkut B. Design, synthesis and biological evaluation of novel N-pyridyl-hydrazone derivatives as potential monoamine oxidase (MAO) inhibitors. Molecules. 2018;23(1):113.
   PubMed Web of Science ®Google Scholar
• Carradori S, Ortuso F, Petzer A, Bagetta D, De Monte C, Secci D, De Vita D, Guglielmi P, Zengin G, Aktumsek A, et al. Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents. Eur J Med Chem. 2018;143:1543–1552.
   PubMed Web of Science ®Google Scholar
• Tok F, Koçyiğit-Kaymakçıoğlu B, Sağlık BN, Levent S, Özkay Y, Kaplancıklı ZA. Synthesis.and biological evaluation of new pyrazolone schiff bases as monoamine oxidase and cholinesterase inhibitors. Bioorg Chem. 2019;84:41–50.
   PubMed Web of Science ®Google Scholar
• Vishnu MS, Pavankumar V, Kumar S, Raja AS. Experimental and computational evaluation of piperonylic acid derived hydrazones bearing isatin moieties as dual inhibitors of cholinesterases and monoamine oxidases. Chemmedchem. 2019;14(14):1359–1376.
   PubMed Web of Science ®Google Scholar
• Palakkathondi A, Oh JM, Dev S, Rangarajan TM, Kaipakasseri S, Kavully FS, Gambacorta N, Nicolotti O, Kim H, Mathew B. (Hetero-)(arylidene)arylhydrazides as multitarget-directed monoamine oxidase inhibitors. ACS Comb Sci. 2020;22(11):592–599.
   PubMed Web of Science ®Google Scholar
• Çevik UA, Osmaniye D, Sağlik BN, Çavuşoğlu BK, Levent S, Karaduman AB, Ilgin S, Karaburun AÇ, Özkay Y, Kaplancikli ZA, et al. Multifunctional quinoxaline-hydrazone derivatives with acetylcholinesterase and monoamine oxidases inhibitory activities as potential agents against Alzheimer’s disease. Med Chem Res. 2020;29(6):1000–1011.
   Web of Science ®Google Scholar
• Saleem Khan M, Asif Nawaz M, Jalil S, Rashid F, Hameed A, Asari A, Mohamad H, Ur Rehman A, Iftikhar M, Iqbal J, et al. Deep eutectic solvent mediated synthesis of 3,4-dihydropyrimidin-2(1H)-ones and evaluation of biological activities targeting neurodegenerative disorders. Bioorg Chem. 2022;118:105457.
   PubMed Web of Science ®Google Scholar
• Jia Z, Wen H, Huang S, Luo Y, Gao J, Wang R, Wan K, Xue W. Click assembly of novel dual inhibitors of AChE and MAO-B from pyridoxine derivatives for the treatment of Alzheimer’s disease. Heterocycl Commun. 2022;28(1):18–25.
   Web of Science ®Google Scholar
• Ye C, Xu R, Cao Z, Song Q, Yu G, Shi Y, Liu Z, Liu X, Deng Y. Design, synthesis, and in vitro evaluation of 4-aminoalkyl-1(2H)-phthalazinones as potential multifunctional anti-Alzheimer’s disease agents. Bioorg Chem. 2021;111:104895.
   PubMed Web of Science ®Google Scholar
• Zhu G, Wang K, Shi J, Zhang P, Yang D, Fan X, Zhang Z, Liu W, Sang Z. The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer’s disease. Bioorg Med Chem Lett. 2019;29(19):126625.
   PubMed Web of Science ®Google Scholar
• Kosak U, Strasek N, Knez D, Jukic M, Zakelj S, Zahirovic A, Pislar A, Brazzolotto X, Nachon F, Kos J, et al. N-alkylpiperidine carbamates as potential anti-Alzheimer’s agents. Eur J Med Chem. 2020;197:112282.
   PubMed Web of Science ®Google Scholar
• Guieu B, Lecoutey C, Legay R, Davis A, Sopkova de Oliveira Santos J, Altomare CD, Catto M, Rochais C, Dallemagne P. First synthesis of racemic trans propargylamino-donepezil, a pleiotrope agent able to both inhibit AChE and MAO-B, with potential interest against Alzheimer’s disease. Molecules. 2020;26(1):80.
   PubMed Web of Science ®Google Scholar
• Nadeem MS, Khan JA, Rashid U. Fluoxetine and sertraline based multitarget inhibitors of cholinesterases and monoamine oxidase-A/B for the treatment of Alzheimer’s disease: synthesis, pharmacology and molecular modeling studies. Int J Biol Macromol. 2021;193(Pt A):19–26.
   PubMedGoogle Scholar
• Javed MA, Bibi S, Jan MS, Ikram M, Zaidi A, Farooq U, Sadiq A, Rashid U. Diclofenac derivatives as concomitant inhibitors of cholinesterase, monoamine oxidase, cyclooxygenase-2 and 5-lipoxygenase for the treatment of Alzheimer’s disease: Synthesis, pharmacology, toxicity and docking studies. RSC Adv. 2022;12(35):22503–22517.
   PubMed Web of Science ®Google Scholar